| Date | Time | Source | Headline | Symbol | Company |
| 05/22/2024 | 7:00AM | Business Wire | AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 | NASDAQ:AZN | AstraZeneca PLC |
| 05/21/2024 | 6:44PM | Business Wire | アストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定 | NASDAQ:AZN | AstraZeneca PLC |
| 05/21/2024 | 11:37AM | Business Wire | AstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 an | NASDAQ:AZN | AstraZeneca PLC |
| 05/21/2024 | 11:36AM | Business Wire | AstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030 | NASDAQ:AZN | AstraZeneca PLC |
| 05/21/2024 | 7:18AM | IH Market News | CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News | NASDAQ:AZN | AstraZeneca PLC |
| 05/21/2024 | 6:08AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
| 05/21/2024 | 2:00AM | Business Wire | AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 | NASDAQ:AZN | AstraZeneca PLC |
| 05/20/2024 | 6:32AM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
| 05/19/2024 | 5:17PM | Business Wire | New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease | NASDAQ:AZN | AstraZeneca PLC |
| 05/13/2024 | 7:16AM | IH Market News | Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More | NASDAQ:AZN | AstraZeneca PLC |
| 05/06/2024 | 2:00AM | GlobeNewswire Inc. | Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca | NASDAQ:AZN | AstraZeneca PLC |
| 05/02/2024 | 7:00AM | Business Wire | CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 05/01/2024 | 7:05AM | Business Wire | AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio | NASDAQ:AZN | AstraZeneca PLC |
| 04/29/2024 | 7:00AM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow | NASDAQ:AZN | AstraZeneca PLC |
| 04/25/2024 | 8:00AM | PR Newswire (US) | AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:AZN | AstraZeneca PLC |
| 04/25/2024 | 7:53AM | IH Market News | U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast | NASDAQ:AZN | AstraZeneca PLC |
| 04/25/2024 | 7:52AM | IH Market News | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings | NASDAQ:AZN | AstraZeneca PLC |
| 04/25/2024 | 2:00AM | Business Wire | Q1 2024 results | NASDAQ:AZN | AstraZeneca PLC |
| 04/16/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 04/12/2024 | 7:05AM | IH Market News | Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News | NASDAQ:AZN | AstraZeneca PLC |
| 04/11/2024 | 7:24AM | IH Market News | Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News | NASDAQ:AZN | AstraZeneca PLC |
| 04/11/2024 | 7:00AM | Business Wire | FASENRA approved for treatment of children aged 6 to 11 with severe asthma | NASDAQ:AZN | AstraZeneca PLC |
| 04/05/2024 | 11:10PM | Business Wire | ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors | NASDAQ:AZN | AstraZeneca PLC |
| 04/05/2024 | 9:43PM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors | NASDAQ:AZN | AstraZeneca PLC |
| 04/05/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
| 04/02/2024 | 7:00AM | Business Wire | Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer | NASDAQ:AZN | AstraZeneca PLC |
| 04/02/2024 | 2:00AM | Business Wire | Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer | NASDAQ:AZN | AstraZeneca PLC |
| 04/01/2024 | 7:00AM | Business Wire | VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH | NASDAQ:AZN | AstraZeneca PLC |
| 03/27/2024 | 6:54AM | IH Market News | GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News | NASDAQ:AZN | AstraZeneca PLC |
| 03/26/2024 | 7:20AM | IH Market News | Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News | NASDAQ:AZN | AstraZeneca PLC |